New combo therapy aims to wipe out rectal cancer before surgery

NCT ID NCT07281768

First seen Jan 07, 2026 · Last updated May 16, 2026 · Updated 21 times

Summary

This study tests whether adding immunotherapy drugs (cemiplimab alone or with fianlimab or REGN7075) to standard chemotherapy can improve outcomes for people with locally advanced rectal cancer before they have surgery. About 66 adults with a specific type of rectal cancer (MSS) that hasn't spread will receive the drug combination, then have surgery to see if the cancer is completely gone. The main goal is to see how many patients have no cancer cells left in the removed tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21287, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.